•  
  •  



Nucleotide-binding and oligomerization domain-like receptor protein 3 inflammasome expression and activation in multiple sclerosis
حيدر فيصل غازي
Authors : Raghda A. Hussein, Haider F. Ghazi, Nawfal M. Sheaheed
Aim: Inflammasome pathway has been linked in the pathogenesis of multiple sclerosis (MS) disease and its expression may be linked to the response to treatment. This study aims to evaluate inflammasome protein and mRNA expression and activating cytokines (interleukin [IL] 1B and IL18) in MS patients undergoing the first line and second line of treatment. Materials and Methods: In this study, 60 MS patients whom attended the MS clinic in the medical city of Baghdad. 30 from them on the first-line drug which includes interferon-beta and 30 on the second-line drugs which include fingolimod and natalizumab and 30 apparently healthy controls included in this study. Nucleotide-binding and oligomerization domain-like receptor protein 3 (NLRP3) mRNA expression was evaluated using quantitative real-time polymerase chain reaction and NLRP3, IL-18, and IL-1β plasma level were estimated by enzyme-linked immunosorbent assay. Results: This study found that the mRNA expression of NLRP3 was significantly higher in patients compared to controls (P < 0.001), as well as the plasma concentration of NLRP3, IL-18, and IL-1β was significantly higher in patients than controls (P < 0.001). In another hand, this study found that there is no significant difference in the expression of NLRP3 and the plasma level of NLRP3, IL-18, and IL-1β between patients who are on the first line and those on the second-line drugs (P = 0.382, 0.449, 0.197, and 0.327, respectively). Conclusion: The NLRP3 expression and activation might govern the inflammatory process in MS disease, and it might be affected equally by treatment with the first line and second line of treatment.

(FULL ARTICLE LINK) Read more ...
1/3/2019